Long-Term Data Support Non-Hormonal Drug for Hot-Flash Management
CHICAGO -- The non-hormonal drug elinzanetant reduced the frequency of moderate-to-severe hot flashes in postmenopausal women, and seemed to have ...
Day: September 15, 2024
Worse PFS Seen with Nivolumab-Rucaparib in Ovarian Cancer
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly ...
Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival
Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived significantly longer when they received enzalutamide ...
‘Is It Safe to Hit a Kid in the Head 200 Times?’: What We Heard This Week
"Is it safe to hit a kid in the head 200 times?" -- Chris Nowinski, PhD, of the Concussion Legacy ...
T-DXd Effective in Some With HER2+ Breast Cancer
A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those ...
Haunting Questions About a Lethal American Virus
Claire Panosian Dunavan is a professor of medicine and infectious diseases at the David Geffen School of Medicine at UCLA ...
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer
Combining retifanlimab (Zynyz) with standard-of-care chemotherapy significantly improved progression-free survival (PFS) in treatment-naïve patients with locally advanced or metastatic squamous ...
A New Option to Treat Intermediate Hepatocellular Carcinoma?
BARCELONA — Adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival in patients ...
How many of us will end up being diagnosed?
BBCThe number of people taking ADHD medication is at a record high – and the NHS is feeling the strain ...
